drugset / Trial / NCT00893607

Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum

NCT00893607 ↗

Phase 1 Completed 24 enrolled Norgine
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study to assess the effects of 10mg NRL001 on mean anal resting pressure (MARP) when administered as a slow release suppository applied to the anal canal or rectum. In addition, the pharmacokinetics of NRL001 in plasma, adverse events, and any changes in heart rate or blood pressure were to be assessed.

Timeline

Start
2007-04
Primary completion
2007-08
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NRL001 Small molecule 10 mg —

Indications

No indication recorded.